Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evogene ( (EVGN) ) has provided an announcement.
On September 10, 2025, Evogene Ltd. announced a strategic collaboration with Google Cloud to enhance its AI-driven molecular discovery platform, ChemPass AI. This partnership aims to accelerate innovation in drug discovery and agriculture by leveraging Google’s infrastructure to optimize molecular design across multiple parameters, significantly improving accuracy and efficiency. This collaboration is expected to strengthen Evogene’s market position by expanding its capabilities in delivering innovative solutions to the pharmaceutical and agricultural sectors.
The most recent analyst rating on (EVGN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene’s overall stock score is primarily impacted by its weak financial performance, marked by persistent losses and negative cash flow. While technical analysis shows a neutral trend, and strategic initiatives from the earnings call are promising, the negative valuation metrics and ongoing financial challenges weigh heavily on the score.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. operates in the biotechnology industry, focusing on the development of novel small molecules for the pharmaceutical and agricultural chemical sectors. Utilizing a proprietary AI engine, the company designs highly potent molecules optimized across multiple parameters, aiming to address real-world commercial product needs.
Average Trading Volume: 197,181
Technical Sentiment Signal: Sell
Current Market Cap: $11.07M
For a thorough assessment of EVGN stock, go to TipRanks’ Stock Analysis page.